Fortune Brands Innovations heads into the final week of May with a striking split: the stock just posted its best week of the year while short sellers scrambled to cover and options traders pivoted to their most bullish stance in months.
The price action tells the opening story. FBIN closed at $38.40, up 15% on the week — a dramatic reversal after a month that had seen the stock shed more than 7%. The rally was not driven by FBIN alone. Close peers also moved sharply higher: AMWD gained nearly 20% on the week, MBC rose 17%, and BLDR, OC, and TREX each added 6–7%. A broad building-products re-rating drove much of the week's gains, though FBIN's move topped the peer group.
The positioning data is where the week gets interesting. Short interest climbed to a 30-day peak of 9.5% of the free float on May 22, then collapsed. A single-day drop of nearly 12% on May 26 pulled the SI % FF back to 8.4%, erasing the spike almost entirely. The build from mid-April — when short interest sat near 7% — has not been fully unwound, and on a one-month basis shorts are still up around 21% in share count. That longer-run trend is worth watching. Borrow costs remain very cheap at 0.47%, down about 9% on the week and well below anything that would register as a squeeze signal. Availability is wide open at 667% of short interest, meaning the lending pool is deep relative to what's borrowed — there is no supply constraint on the short side.
Options tell a very different story. The put/call ratio has cratered to 0.13 — close to its 52-week low of 0.03 and nearly 1.5 standard deviations below the 20-day average of 0.68. As recently as early May the PCR was running above 1.0, reflecting heavy downside hedging around the May 7 earnings release. That hedging has been almost entirely unwound. The options market is now heavily skewed toward calls, the most bullishly positioned it has been all year.
The Street is less enthusiastic. Analyst targets have moved uniformly lower in recent weeks. JP Morgan's Michael Rehaut cut his target to $39 from $42 on May 15. Barclays trimmed to $41 from $43 on May 11. Following the May earnings print, UBS, Truist, RBC, and Evercore all lowered targets while keeping ratings unchanged. The consensus still leans toward buy, with a mean price target of $46.64 — implying about 21% upside from current levels. But the direction of analyst movement has been consistently negative, and the factor scores reinforce the caution: EPS momentum ranks in the 11th percentile on a 30-day basis and the 15th on a 90-day basis, flagging a deteriorating estimates backdrop. The bear case centres on weakness in the China-facing water innovations segment and a cut to full-year volume guidance. Bulls point to portfolio diversity, brand strength, and a valuation that now screens as reasonable: PE is running at 11.5x and EV/EBITDA near 8.8x, both below pre-earnings levels.
The most notable ownership development this week came from the board. Edward Garden of Trian — represented on the board through Garden Investment Management — bought more than 466,000 shares between May 19 and May 20, spending roughly $15.7 million at prices in the $33–$35 range. That's a substantial commitment at prices well below the current close, and it follows the company's recent leadership transition, including a new CEO. Garden Investment already held over 3.5 million shares prior to these purchases. The move stands out against the backdrop of executive selling at $52 earlier in the year, which now looks prescient in hindsight.
The ORTEX short score ticked down to 49.9 on May 26 after briefly touching 60 mid-week, consistent with the partial short covering. With next earnings confirmed for July 28, the period between now and that print will test whether the week's sharp rally reflects genuine re-rating or positioning-driven noise — and whether the building-products sector tailwind can offset the persistent drag from China and the still-elevated short base.
See the live data behind this article on ORTEX.
Open FBIN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
